Alx Oncology Holdings (ALXO) Common Equity (2019 - 2026)

Alx Oncology Holdings has reported Common Equity for 8 years, with the latest figure at $151.3 million in Q1 2026.

• Quarterly Common Equity rose 71.41% year-over-year to $151.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $151.3 million (up 71.41% YoY) and the FY2025 annual result came in at $26.0 million, down 77.13% from the prior year.
• Common Equity advanced to $151.3 million in Q1 2026 per ALXO's latest filing, from $26.0 million in the prior quarter.
• Over five years, Common Equity peaked at $343.6 million in Q1 2022 and troughed at $26.0 million in Q4 2025.
• A 5-year average of $174.7 million and a median of $164.2 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2025 and 2026: Common Equity tumbled 77.13% in 2025, then soared 71.41% in 2026.
• Over 5 years, Common Equity stood at $263.5 million in 2022, then slipped by 27.99% to $189.7 million in 2023, then slumped by 40.11% to $113.6 million in 2024, then sank by 77.13% to $26.0 million in 2025, then jumped by 482.53% to $151.3 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $151.3 million, $26.0 million, and $44.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.